FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 320:277-281 February 2, 1989 Number 5 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We investigated the parathyroid hormone-1,25-dihydroxyvitamin D3 (1,25(OH)2D) axis in osteoporosis by administering phosphate to 8 postmenopausal women with osteoporosis (49 to 78 years old) and to 10 normal women matched for age (50 to 74 years). All subjects responded with a similar increase in the serum phosphorus concentration (women with osteoporosis, 1.15 +/- 0.06 to 1.79 +/- 0.09 mmol per liter; controls, 1.14 +/- 0.05 to 1.73 +/- 0.08 mmol per liter) and a fall in the ionized calcium concentration (women with osteoporosis, 1.12 +/- 0.03 to 1.06 +/- 0.03 mmol per liter; controls, 1.17 +/- 0.01 to 1.11 +/- 0.02 mmol per liter). Parathyroid hormone levels rose 2.5-fold in the control group (15.4 +/- 2.2 to 37.9 +/- 6.1 pg per milliliter) but increased by only 43 percent in the group with osteoporosis (14.8 +/- 2.8 to 21.2 +/- 4.1 pg per milliliter), an increase similar to that previously reported in young normal subjects (53 percent). In healthy older and younger subjects, the levels of 1,25(OH)2D did not change; in the subjects with osteoporosis, however, they decreased significantly (50 percent). We conclude that older women require a greater parathyroid hormone stimulus than younger women to maintain vitamin D homeostasis, because of an age-related decline in the formation of 1,25(OH)2D in response to parathyroid hormone, and that in osteoporosis the age-appropriate parathyroid hormone response to the same hypocalcemic signal is diminished. Our results are consistent with the presence of an abnormality in parathyroid hormone secretory function in osteoporosis in addition to the universal decline in 1,25(OH)2D responsiveness associated with aging.

Source Information

Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032.

This article has been cited by other articles:

• Dhingra, R., Sullivan, L. M., Fox, C. S., Wang, T. J., D'Agostino, R. B. Sr, Gaziano, J. M., Vasan, R. S. (2007). Relations of Serum Phosphorus and Calcium Levels to the Incidence of Cardiovascular Disease in the Community. Arch Intern Med 167: 879-885 [Abstract] [Full Text]  
• Ahmad, A. M., Hopkins, M. T., Thomas, J., Durham, B. H., Fraser, W. D., Vora, J. P. (2004). Parathyroid responsiveness to hypocalcemic and hypercalcemic stimuli in adult growth hormone deficiency after growth hormone replacement. Am. J. Physiol. Endocrinol. Metab. 286: E986-E993 [Abstract] [Full Text]  
• Sax, L. (2001). The Institute of Medicine's "Dietary Reference Intake" for Phosphorus: A Critical Perspective. J. Am. Coll. Nutr. 20: 271-278 [Abstract] [Full Text]  
• Russell, R. M (2000). The aging process as a modifier of metabolism. Am. J. Clin. Nutr. 72: 529S-532 [Abstract] [Full Text]  
• Kurland, E. S., Rosen, C. J., Cosman, F., McMahon, D., Chan, F., Shane, E., Lindsay, R., Dempster, D., Bilezikian, J. P. (1997). Insulin-Like Growth Factor-I in Men with Idiopathic Osteoporosis. J. Clin. Endocrinol. Metab. 82: 2799-2805 [Abstract] [Full Text]  
• Orwoll, E. S., Oviatt, S. K., McClung, M. R., Deftos, L. J., Sexton, G. (1990). The Rate of Bone Mineral Loss in Normal Men and the Effects of Calcium and Cholecalciferol Supplementation. ANN INTERN MED 112: 29-34 [Abstract]